A Prospective Study of the Dry Eye Drink That Evaluates Hydration and Subject's Assessment on Eye Dryness

Bruder Healthcare

Status

Completed

Conditions

Dry Eye

Treatments

Dietary Supplement: Dry Eye Drink

Study type

Interventional

Funder types

NETWORK

Industry

Identifiers

NCT05949697

MW230012

Details and patient eligibility

About

A study to assess the effect of the Dry Eye Drink on eye dryness

Full description

This is a prospective, non-randomized, comparative study of the Dry Eye Drink by Bruder Healthcare that evaluates hydration and subject's assessment on eye dryness. Subjects will administer the Dry Eye Drink by adding one sachet of the Dry Eye Drink powder in 12 Oz of water.

Enrollment

60 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male and/or female subjects aged between 18 and 65 years (both limits inclusive).
Subjects with symptomatic Dry Eye Syndrome confirmed at baseline in at least any one or both the eyes.
Subjects with ≥ 310 mOsmol/L tear osmolarity.
Subjects with ≥ 6 SPEED score.
Subject willing to provide written informed consent and able to comply with protocol requirements.

Exclusion criteria

Subjects who are pregnant, nursing, or planning a pregnancy within the study participation period.
Have undergone mechanical treatment for meibomian gland dysfunction using thermal pulsation/expression (e.g., LipiFlow) or intense pulsed light (e.g., OptiLight) therapy within 6 months prior to the Screening/Baseline Visit
Have a known hypersensitivity to any of the study product components
Have undergone ocular surgery (e.g., cataract, corneal or refractive surgical procedure) within 6 months prior to the Screening/Baseline Visit
Have evidence of clinically significant ocular trauma
Have active ocular Herpes simplex or Herpes Zoster infection
Have ocular inflammation (uveitis, iritis, scleritis, episcleritis, conjunctivitis or keratitis, with the exception of keratoconjunctivitis sicca) at the discretion of the investigator
Have ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids. including hordeolum)
Have severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis)
Have eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis)
Have an ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity)
Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
Participation in any clinical study within 30 days before the first administration of study product.
Subjects who are illiterate and cannot complete the subject diary independently.